N oroviruses (NoVs) are the leading cause of severe viral gastroenteritis worldwide, causing ϳ50% of all acute gastroenteritis outbreaks in the United States and Europe (1) . Disease severity is usually moderate, but morbidity and mortality rates due to NoV infection are increasingly becoming evident, with particularly high tolls taken on children and immunocompromised and aged populations (2) (3) (4) (5) (6) (7) (8) (9) , resulting in an estimated 200,000 deaths per year (10) . In addition, postinfectious irritable bowel syndrome develops in a substantial portion of patients (11) . These groups of people, in addition to military personnel, childcare and health care providers, and food handlers, would benefit from a NoV vaccine. Recent success has been demonstrated for a monovalent Norwalk virus VLP-based vaccine (12) , but significant obstacles remain for the development of a broadly protective NoV vaccine, including the lack of a clear understanding of the complex antigenic relationships between the many NoV strains and the interaction between these strains and the host immune system over time.
Noroviruses contain positive-sense, single-stranded RNA genomes, and phylogenetic classification is based on the amino acid sequence of the major capsid protein encoded by ORF2 (13) . Genogroup I (GI) and GII cause most human infections, and each genogroup is further subdivided into 9 and 21 different genotypes, respectively (1, 13) . Exogenous expression of ORF2, the major capsid protein, results in virus-like particle (VLP) self-assembly. Each particle is composed of 90 copies of the major capsid protein dimer and a small number of copies of the ORF3-encoded minor capsid protein (14, 15) . The capsid monomer is divided into two structural domains. The shell domain (S) forms the core of the particle and the protruding domain (P) extends away from the central core. The P domain is further divided into two subdomains: P1 consists of residues 226 to 278 and residues 406 to 520 and forms the stalks that support the extended, surface-exposed P2 subdomain (residues 279 to 405) (14) . The P2 subdomain interacts with potential neutralizing/blockade antibodies and the NoV carbohydrate-binding ligands, the histo-blood group antigens (HBGAs) (16) (17) (18) (19) (20) (21) (22) . Coinciding with these functions, changes in the P2 amino acid sequence of GII.4 strains occur frequently and correlate with the emergence of new epidemic strains with altered carbohydrate ligand binding and antigenicity profiles (16, 20, (23) (24) (25) (26) (27) (28) (29) . The study of neutralization antibodies and epitopes is hindered by the lack of a cell culture or small animal model for human norovirus propagation. Therefore, we developed an in vitro surrogate neutralization assay that measures the ability of an antibody to block binding of a VLP to a carbohydrate ligand (16, 20, 30, 31) . The blockade assay has been verified as a surrogate neutralization assay in infected chimpanzees (32) and Norwalk virus-infected humans (12, 33) . Importantly, the blockade assay has been shown to differentiate between GII.4 strains antigenically too similar to be distinguished from each other by traditional EIAs (16, 20, 34) . This enhanced sensitivity has been crucial in mapping GII.4 evolving blockade epitopes.
GII.4 strains have caused the majority of all norovirus outbreaks over the past 2 decades. Four GII.4 pandemics, each caused by a newly emergent GII.4 variant strain, have been characterized using molecular epidemiological methods. Strain US95/96 (GII. 4.1997) caused the pandemic that occurred during the mid1990s (35, 36) . The second pandemic began in 2002 with the emergence of the Farmington Hills strain (GII. 4.2002) (37) (43) .
Comparing the monoclonal antibody (MAb) reactivity of different GII.4 strains that have circulated over the past 2 decades has clearly demonstrated that new strain emergence is associated with changes in blockade antibody epitopes (20, 34) . We and others have used bioinformatic tools to predict potential evolving epitopes. Residues 296 to 298 and residues 393 to 395 are consistently identified by different groups as putative epitopes that change between epidemic GII.4 strains. Surface residues at positions 333, 340, 356, 368, 372, 407, and 412 to 413 have also been predicted as antibody epitopes (16, 23, 24, 27, 38, (44) (45) (46) (47) . These amino acids cluster within the P2 subdomain, where they would be most available on the capsid surface for interactions with antibodies. Although bioinformatic predictions are useful, few studies have tested these predictions. Allen et al. (46) compared the VLPbinding reactivity of five MAbs against one pre-and one post-2002 pandemic GII.4 strain and found two conformational epitopes as differing between the two strains. Site A includes amino acids 294 to 296. Site B includes amino acids 393 to 395 and confirmed residue 395 as an important antigenic determinant in the GII.4.2002 Farmington Hills strain (16) . Further, our group has used both human and mouse anti-NoV MAbs coupled with molecular biology approaches to exchange predicted epitopes between GII.4 strain backbones to identify evolving blockade epitopes between GII.4 strains that have circulated from 1987 until 2009. Using this novel approach we have identified three evolving blockade GII.4 antibody epitopes (20) (21) (22) . Epitope A is comprised of amino acids 294, 296 to 298, 368, and 372 and is a highly variable blockade epitope that changes with new GII.4 strain emergence. Monoclonal human and mouse antibodies against epitope A have been described as highly strain selective, lacking reactivity to other GII.4 strains chronologically removed from the immunizing strain. GII.4.2006 and GII.4.2009 were found to differ in reactivity to a human MAb targeting epitope A, establishing a difference in human neutralizing epitopes between these two strains and supporting escape from herd immunity by antigenic variation at neutralizing epitopes as a mechanism for new NoV strain emergence. Epitope D (residues 393 to 395) has also been confirmed as an evolving blockade epitope using human antiNoV MAbs. These findings are particularly interesting as epitope D has been shown to modulate HBGA binding of GII.4 strains, supporting the suggested correlation between epitope escape from herd immunity and altered HBGA binding (16 
MATERIALS AND METHODS
VLPs. For all constructs except GII.4.2009, the synthetically derived, epitope-engineered or outbreak strain ORF2 genes were inserted directly into the VEE replicon vector for the production of virus replicon particles (VRPs) as previously described by our group (20, 22) . Virus-like particles (VLPs) were expressed in VRP-infected BHK cells and purified by velocity sedimentation in sucrose, followed by simultaneous concentration and dialysis into phosphate-buffered saline (PBS) using a 100-kDa MWCO centrifugal filter units (Millipore). GII. 4.2009 (21) VLPs were expressed in the baculovirus system, concentrated by centrifugation through 40% sucrose, and purified by cesium chloride gradient centrifugation. VLPs were resuspended in PBS. VLP protein concentrations were determined by a BCA protein assay (Pierce, Rockford, IL). The structural integrity of epitope engineered VLPs was confirmed by electron microscopy, enzymelinked immunosorbent assay (ELISA), and carbohydrate binding as described previously (20) .
EIAs. Mouse MAb reactivity was determined by enzyme immunoassay (EIA), as reported (20, 21) . Briefly, plates were coated at 1 g of VLP/ml in PBS before the addition of 1 g of purified IgG/ml. Primary antibody incubation was followed by anti-mouse IgG-HRP (GE Healthcare) and color development with One-Step Ultra TMB ELISA HRP substrate solution (Thermo Fisher). Each step was followed by washing with PBS-0.05% Tween 20, and all antibodies were diluted in 5% dry milk in PBS-0.05% Tween 20. The data shown represent the average of at least three replicates and are representative of similar data from at least two independent trials. Establishment of EIAs using new MAbs included PBScoated wells as negative controls and polyclonal anti-norovirus mouse sera as positive controls. Antibodies were considered positive for reactivity if the mean optical density at 450 nm after background subtraction for VLP-coated wells was Ͼ0.2 (48) .
VLP-carbohydrate ligand-binding antibody blockade assays. Pig gastric mucin type III (PGM; Sigma Chemicals) has been validated as a substrate for NoV VLP antibody blockade assays (21, 22) . PGM contains relatively high levels of H and A antigen and more moderate levels of Lewis Y antigen (21) . The VLPs used in the blockade assays in the present study bind to both PGM and synthetic biotinylated-HBGA, and binding to PGM is consistent with synthetic Bi-HBGA binding profiles for ␣-1,2-fucose (H antigen) and ␣-1,4-fucose (Lewis antigen) containing molecules (16, 21, 49) . For blockade assays, PGM was solvated in PBS at 5 mg/ml, coated onto EIA plates at 10 g/ml in PBS for 4 h, and blocked overnight at 4°C in 5% dry milk in PBS-0.05% Tween 20. VLPs (0.5 g/ml) were pretreated with decreasing concentrations of test MAb or outbreak sera for 1 h at room temperature before being added to the carbohydrate ligand-coated plates for 1 h. Bound VLP were detected by a rabbit anti-GII norovirus polyclonal sera made from hyperimmunization with either GII.4.2009 or a cocktail of GII.4.1997, GII.3.1999, GII.1.1976, and GII.2.1976 VLPs, followed by anti-rabbit IgG-HRP (GE Healthcare) and color developed with 1-Step Ultra TMB ELISA HRP substrate solution (Thermo Fisher). The percent control binding was defined as the binding level in the presence of antibody pretreatment compared to the binding level in the absence of antibody pretreatment multiplied by 100. All incubations were performed at room temperature. Each step was followed by washing with PBS-0.05% Tween 20, and all reagents were diluted in 5% dry milk in PBS-0.05% Tween 20. All antibodies were tested for blockade potential against GII.4 VLPs at 2-fold serial dilutions ranging from 0.08 to 2 g of MAb/ml or 0.008 to 1% outbreak serum. Additional concentrations of purified antibodies were tested if needed to complete the sigmoid dose-response curve. The data shown represent the averages of at least two replicates and are representative of similar data from at least two independent trials. Blockade data were fit using sigmoidal dose-response analysis of nonlinear data in GraphPad Prism. The 50% effective concentration (EC 50 ) values were calculated for antibodies that demonstrated a dose-dependent (Hill slope Յ Ϫ0.7) blockade of at least 50% at the dilution series tested. MAbs that did not block 50% of binding at the highest dilution tested were assigned an EC 50 of 2ϫ the assay upper limit of detection. Standard error was used to calculate the 95% confidence intervals (CI), and EC 50 values between VLPs were compared using one-way analysis of variance with Dunnett's post test, when at least three values were compared or a Student t test when only two values were compared. A difference was considered significant if the P value was Ͻ0.05. Of note, VLP concentrations in blockade assays are in the low nanomolar range and therefore cannot discriminate between antibodies with subnanomolar affinities.
Mouse immunization, hybridoma production, and IgG purification. MAbs to GII.4.2009 were produced and purified as described earlier (21) . Swiss-Webster mice were immunized on days 0, 20, 40, and 80 with 50 g of VLP in PBS plus 50 l of GERBU adjuvant (Fisher Scientific) for a total of 100 l, and splenocytes were fused on day 84. The resulting hybridomas underwent two rounds of limited dilution subcloning, were isotyped (Roche), and were purified by protein G chromatography (GE Healthcare).
Commercial MAbs. Commercial MAbs MAB223P, MAB224P, MAB225P, and MAB226P were developed against GII.4.2006 VLPs in collaboration with Maine Biotechnology (Portland, ME).
GII.4 outbreak serum samples. Deidentified convalescent-phase serum samples from eight subjects infected with GII.4.2009 during an outbreak that occurred in March 2010 were studied. Acute-and convalescent-phase serum samples were collected 3 to 4 days and 21 days after the onset of illness, respectively. Infection was defined as (i) IgA seroconversion as measured by EIA against GII.4.2009-VLPs and (ii) virus shedding in stool samples as detected by GI and GII NoV TaqMan real-time reverse transcription-PCR (RT-PCR) (42) . Norovirus-positive samples were genotyped by sequencing the RT-PCR product from diagnostic regions C and D (50, 51) . Sequence alignment of the outbreak strain and reference NoV genotypes was performed using the CLUSTAL W algorithm. Phylogenetic analysis was performed using TreeCon software (52) , and phylogenetic trees were constructed using the neighbor-joining method. The P2 subdomain for each positive sample was amplified and sequenced (42) (Table 1) . First, we characterized these MAbs for reactivity to an assortment of NoV VLPs, including strains from both genogroups and a set of time-ordered GII.4 VLPs (20) . All four commercial MAbs demonstrated broad reactivity with GII. 
RESULTS
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suggests that a more sensitive measure of antigenic variation is required to identify functional antigenic changes. The antibodymediated VLP-carbohydrate blockade assay measures the potential neutralization activity of an antibody and has proven to be highly differential between similar GII.4 NoV strains (16, 20) . Therefore, each of the above-described MAbs was tested for blockade activity against both GII. amino acid similarity within the P2 subdomain. Despite this high degree of similarity, the two strains vary at two previously identified blockade epitopes (Fig. 2) (20) . Epitope E varies at V413I, a conserved amino acid change. Epitope A varies at A294P, S368A, and E372D, three of the six amino acids that comprise this immunodominant epitope (20, 22) . To test whether variation in epitope A, D, or E accounts for the differences between GII.4.2006 and GII.4.2009 identified in blockade assays (Fig. 1) , each blockade MAb was screened for EIA reactivity to GII.4.2006 VLPs containing alterations in blockade epitopes A, D, and E, previously confirmed as blockade antibody targets (20) (21) (22) . In each case the GII.4.2006 epitope amino acids were replaced with the amino acids found in the GII.4.1987 epitope (Fig. 2) (Fig. 2) . This chimeric VLP has three common epitope A amino acid residues (residues 296, 297, and 298) and three amino acid differences (residues 294, 368, and 372) between GII. Table 2 ). Significant amounts of blockade activity were restored to these antibodies when only three amino acids were replaced (residues 294, 368, and 372 in GII. 4 (Fig. 1) and, subsequently, the exchange of epitope A, D, or E amino acids had no significant impact on blockade activity of these MAbs (Fig. 3C, Table 2 , and data not shown). Further, although both of these MAbs block GII. (Fig. 4 and 5B), confirming the increased sensitivity of the blockade assay compared to the single-dilution EIA. had no impact on blockade activity of NO66, NO193, and NO224, indicating that these MAbs do not target epitope A (Fig. 5C and Table 3 ). Epitope A is a primary target for blockade antibodies in human polyclonal sera following GII. 4 (Fig. 6) . To determine the impact epitope A may have on the human polyclonal antibody response to NoV infection, we compared VLP blockade activity of convalescent-phase serum collected from individuals infected with GII. 4.2009 (Fig. 7) . GII. 4 
DISCUSSION
GII.4 NoV strains have circulated worldwide for at least the past 2 decades, despite high population seroprevalence, leading some to conclude that NoVs induce only short-term or nonprotective immune responses that allow repeated strain infection. However, the detailed study of GII.4 strains that circulated from 1987 until 2012 at the bioinformatics level suggests that the GII.4 strains are complex and divergent from each other, as new strains emerge and replace ancestral strains. The viral evolution identified by bioinformatics has been confirmed by experimental data indicating that different GII.4 strains exhibit different RNA-dependent RNA polymerase rates (24) , ligand-binding properties (16, 28) , and antigenicity (16, 20, 34) . Specifically, new GII.4 norovirus strain emergence is associated with changes in antibody blockade epitopes (20) (21) (22) , supporting the hypothesis that GII. Fig. 1 and 4) . These data support the hypothesis that the emergence of GII.4.2009 is associated with changes in blockade/neutralizing epitopes and subsequent loss of protective herd immunity, as previously described 
FIG 6
Summary of GII.4 MAb epitopes described in the present study. Antibody epitopes were determined to be conformational or linear based on Western blot reactivity. Binding of seven of the MAbs was dependent upon epitope A residues (light gray boxes). The impact of amino acids that comprise epitope A on each MAb were designated as either essential for blockade activity (dark gray boxes) or sufficient for complete blockade activity (black boxes) or had no effect on blockade activity (white boxes) as described in Fig. 3 and 5. for other GII.4 strains (16, 20, 22, 34) and other RNA viruses such as influenza virus (54) (55) (56) and HIV and HCV (57) . Epitope A, a previously identified blockade epitope (20, 22) , differs between GII.4.2006 and GII. 4.2009 . Predicted epitope A is conformation dependent and consists minimally of varying amino acid residues 294, 296, 297, 298, 368, and 372. Amino acid combinations including these residues have been predicted to form antibody epitopes by other groups as well (45, 46) . Epitope A is targeted by a significant portion of isolated MAbs as well as polyclonal antibody responses elicited in both norovirus-immunized mice (22) and infected humans (Fig. 7) (20) , indicating a primary function in the overall anti-GII. 4 , and 372 were changed compared to homotypic VLP blockade activity. However, this MAb did not detect VLPs by Western blotting. NO52 provides an additional epitope A binding pattern characterized by almost all of the blockade activity conferred by the conformational amino acids 294, 368, and 372. These varied patterns of epitope A reactivity suggest that amino acids 294, 296 to 298, 368, and 372 actually constitute several distinct, overlapping blockade antibody epitopes, and our panel of MAbs consists of individual antibodies that bind to different combinations of amino acids that include components of epitope A, in particular residues 296 to 298. This suggestion is supported by the diverse EIA reactivity patterns documented for several of these MAbs now defined as epitope A dependent. Interestingly, these diverse strain EIA reactivity patterns coupled with highly selective blockade patterns are contrary to findings with human MAbs that recognize epitope A. Previous studies with human MAbs demonstrated that epitope A has a complex reactivity pattern between strains (20) . Three of seven anti-GII.4 MAbs developed from a healthy individual of unknown NoV exposure history were targeted to epitope A. One MAb only recognized and blocked epitope A as it is presented in the early strains GII. 4.1987 and GII. 4.1997 . Two other MAbs only recognized and blocked epitope A as it is presented in GII. 4.2006 and GII.4.2009 , although significantly more antibody was needed to block GII.4.2009 than was needed to block GII. 4.2006 . Similar but very limited crossstrain blockade activity was also shown for mouse MAbs that bind to epitope A (22, 34) , but, surprisingly, mouse MAbs targeting epitope A display a wider EIA binding profile than human MAbs directed to epitope A (22, 34) , possibly suggesting a difference in norovirus antibody specificity between antibodies that result from hyperimmunization of mice with VLP and antibodies generated as the result of a life-time of norovirus infection. Crystal structures of GII.4-MAb complexes are needed to fully understand these complex reactivity patterns.
Epitope A is continuing to evolve, likely in response to protective herd immunity, and the data presented here suggest that a surveillance system that monitored changes in epitope A may be an effective predictor of new norovirus strain emergence. Although, at this time, it is unclear exactly how many or which amino acids within epitope A would need to change to result in complete escape from anti-GII.4.2006 immunity, clearly changing five of the six amino acids (294, 297, 298, 368, and 372) results in complete loss of blockade activity of all of the MAbs that are impacted by epitope A sequence while changing only three amino acids (294, 368, and 372) had anywhere from no effect to almost complete restoration of the blockade activity, depending on the antibody tested. The continued viral adaptation of blockade epitopes, including epitope A, will require development of proactive norovirus surveillance systems coupled with a formulation-adaptable vaccine to provide protection from norovirus infection, not unlike the successful approach used for global control of influenza virus. Norovirus surveillance systems have already been established in Europe, Japan, and the United States and shown to be able to rapidly detect newly emerging strains (42) . Mapping of the crucial epitopes for virus neutralization will facilitate the predicative power of these surveillance systems and provide potential vaccine targets.
